{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:03:55Z","timestamp":1790661835658,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, and safer combination strategies with improved antitumor efficacy are still needed. Berberine (BBR), a natural isoquinoline alkaloid with multi-target pharmacological activity, and celecoxib (CXB), a selective cyclooxygenase-2 (COX-2) inhibitor, have shown antitumor potential. However, their combined efficacy and underlying mechanisms in NSCLC remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Network pharmacology, molecular docking, Chou\u2013Talalay combination index analysis, complementary synergy analysis using SynergyFinder+,\n                      <jats:italic>in vitro<\/jats:italic>\n                      functional assays, molecular validation, and a PC9 xenograft model were integrated to evaluate the antitumor effects and associated molecular changes of BBR combined with CXB. Candidate targets and pathways were screened using protein\u2013protein interaction analysis, GO\/KEGG enrichment, and Target\u2013Pathway network analysis. Molecular docking was performed to assess the predicted binding affinity of BBR and CXB with key targets, and native-ligand re-docking was performed to validate the docking protocol. Cell viability, proliferation, colony formation, migration, invasion, apoptosis, and molecular changes were examined using CCK-8, EdU, colony formation, wound-healing, Transwell invasion, flow cytometry, Western blotting, qRT-PCR, immunohistochemistry, and\n                      <jats:italic>in vivo<\/jats:italic>\n                      experiments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Network analysis identified EGFR, AKT1, and PTGS2 (encoding COX-2) as candidate nodes, and molecular docking suggested predicted binding of BBR and CXB with EGFR, AKT1, and COX-2. Native-ligand re-docking showed acceptable reproduction of the crystallographic ligand poses. BBR and CXB synergistically reduced A549 and PC9 cell viability, with ZIP, HSA, Loewe, and Bliss analyses further supporting the multidose synergy, and a representative working combination dose was used for validation. The combination significantly inhibited proliferation, colony formation, migration, and invasion while promoting apoptosis. These effects were accompanied by suppression of EGFR and AKT phosphorylation, reduced COX-2 expression, downregulation of TNF-\u03b1, IL-1\u03b2, and CXCL8, decreased the Bcl-2\/Bax ratio, and increased cleaved-Caspase-3.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , BBR + CXB more effectively inhibited PC9 xenograft growth than either monotherapy without obvious body weight loss, accompanied by reduced Ki-67, p-EGFR, p-AKT, and COX-2 expression and increased cleaved-Caspase-3 staining.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      BBR combined with CXB exhibits synergistic antitumor activity in NSCLC cells and enhanced antitumor efficacy\n                      <jats:italic>in vivo<\/jats:italic>\n                      , associated with suppression of EGFR\/AKT\/COX-2-related signaling, attenuation of inflammatory responses, and activation of apoptosis, providing support for this potential combination strategy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1930125","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:47:45Z","timestamp":1790660865000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Berberine and celecoxib synergistically suppress non-small cell lung cancer with EGFR\/AKT\/COX-2-related signaling: network pharmacology, molecular docking and experimental validation"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Taizhou Fourth People\u2019s Hospital","place":["Taizhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"She","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Jiangsu Province People\u2019s Hospital and The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangsu Province (Suqian) Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Jiangsu Province People\u2019s Hospital and The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Suzhou Municipal Hospital and The Affiliated Suzhou Hospital of Nanjing Medical University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e202402479","DOI":"10.1002\/cbdv.202402479","article-title":"Phytochemicals in cancer therapy: a structured review of mechanisms, challenges, and progress in personalized treatment","volume":"22","author":"Aljabali","year":"2025","journal-title":"Chem. Biodivers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1700048","DOI":"10.1002\/minf.201700048","article-title":"Network-based approaches in pharmacology","volume":"36","author":"Boezio","year":"2017","journal-title":"Mol. Inform."},{"key":"B3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/biology9120434","article-title":"Prostaglandin E2 and cancer: insight into tumor progression and immunity","volume":"9","author":"Finetti","year":"2020","journal-title":"Biol. (Basel)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1433497","DOI":"10.3389\/fonc.2024.1433497","article-title":"Association of COX-inhibitors with cancer patients\u2019 survival under chemotherapy and radiotherapy regimens: a real-world data retrospective cohort analysis","volume":"14","author":"Flausino","year":"2024","journal-title":"Front. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1124\/jpet.113.207118","article-title":"NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?","volume":"348","author":"Fornai","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"108965","DOI":"10.1016\/j.intimp.2022.108965","article-title":"Berberine regulates PADI4-related macrophage function to prevent lung cancer","volume":"110","author":"Gu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1002\/ptr.8255","article-title":"Berberine and berberine nanoformulations in cancer therapy: focusing on lung cancer","volume":"38","author":"Hsu","year":"2024","journal-title":"Phytother. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1099811","DOI":"10.3389\/fonc.2023.1099811","article-title":"Cyclooxygenase-2-Prostaglandin E2 pathway: a key player in tumor-associated immune cells","volume":"13","author":"Jin","year":"2023","journal-title":"Front. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1039\/D5MD00196J","article-title":"Recent advances in targeting COX-2 for cancer therapy: a review","volume":"16","author":"Kassab","year":"2025","journal-title":"RSC Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1691392","DOI":"10.3389\/fphar.2025.1691392","article-title":"Celecoxib in oncology: targeting the COX-2\/PGE2 axis to reprogram the tumor immune microenvironment and enhance multimodal therapy","volume":"16","author":"Kuang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-024-07254-x","article-title":"PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells","volume":"629","author":"Lacher","year":"2024","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"10732748241302902","DOI":"10.1177\/10732748241302902","article-title":"Phytochemicals in cancer chemoprevention: preclinical and clinical studies","volume":"31","author":"Lekhak","year":"2024","journal-title":"Cancer Control."},{"key":"B15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cdt3.120","article-title":"COX-2 in lung cancer: mechanisms, development, and targeted therapies","volume":"10","author":"Liu","year":"2024","journal-title":"Chronic Dis. Transl. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1940-6207.CAPR-11-0078","article-title":"Lung cancer chemoprevention with celecoxib in former smokers","volume":"4","author":"Mao","year":"2011","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3760\/cma.j.cn112137-20240511-01092","article-title":"Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer","volume":"104","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1158\/2159-8290.CD-20-1815","article-title":"Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy","volume":"11","author":"Pelly","year":"2021","journal-title":"Cancer Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1379698","DOI":"10.3389\/fonc.2024.1379698","article-title":"Natural products targeting autophagy and apoptosis in NSCLC: a novel therapeutic strategy","volume":"14","author":"Qin","year":"2024","journal-title":"Front. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7368","DOI":"10.3390\/molecules26237368","article-title":"Berberine as a potential anticancer agent: a comprehensive review","volume":"26","author":"Rauf","year":"2021","journal-title":"Molecules"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1557790","DOI":"10.3389\/fimmu.2025.1557790","article-title":"Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2\/PGE2 signaling pathway in mice","volume":"16","author":"Sakurai","year":"2025","journal-title":"Front. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1124\/pharmrev.123.000901","article-title":"Prostaglandin E2 in the tumor microenvironment, a convoluted affair mediated by EP receptors 2 and 4","volume":"76","author":"Santiso","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/ijms26052049","article-title":"Lung cancer-Epidemiology, pathogenesis, treatment and molecular aspect (review of literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B28","volume-title":"Global Cancer Observatory: Cancer Today","year":"2024"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.3390\/ijms24043257","article-title":"Berberine alleviates doxorubicin-induced myocardial injury and fibrosis by eliminating oxidative stress and mitochondrial damage via promoting Nrf-2 pathway activation","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"7224","DOI":"10.12998\/wjcc.v10.i21.7224","article-title":"Molecular mechanisms of Biyu decoction as treatment for psoriasis: a network pharmacology and molecular docking study","volume":"10","author":"Wang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"B31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/ddr.22061","article-title":"Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K\/AKT pathway","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"23856","DOI":"10.1038\/s41598-025-09767-5","article-title":"Multi-omics and experimental validation reveal mechanism of compound mylabris capsules in treating diffuse large B-cell lymphoma","volume":"15","author":"Wang","year":"","journal-title":"Sci. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1038\/s41598-025-90211-z","article-title":"Integrated network pharmacology, molecular docking and experimental validation to investigate the mechanism of tannic acid in nasopharyngeal cancer","volume":"15","author":"Wang","year":"","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1366260","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"15","author":"Xiang","year":"2024","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.3390\/molecules27144523","article-title":"Anticancer effects and mechanisms of berberine from medicinal herbs: an update review","volume":"27","author":"Xiong","year":"2022","journal-title":"Molecules"},{"key":"B36","doi-asserted-by":"publisher","first-page":"149021","DOI":"10.1016\/j.gene.2024.149021","article-title":"Berberine: a multifaceted agent for lung cancer treatment-from molecular insight to clinical applications","volume":"934","author":"Xu","year":"2025","journal-title":"Gene"},{"key":"B37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.toxlet.2013.12.013","article-title":"Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated \u03b2-catenin pathway","volume":"225","author":"Zhang","year":"2014","journal-title":"Toxicol. Lett."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0223760","DOI":"10.1371\/journal.pone.0223760","article-title":"Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt\/mTOR signaling pathway and COX-2 expression","volume":"14","author":"Zhang","year":"","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2019.00123","article-title":"Network pharmacology databases for traditional Chinese medicine: review and assessment","volume":"10","author":"Zhang","year":"","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12967-025-06144-8","article-title":"Targeting PI3K signaling in lung cancer: advances, challenges and therapeutic opportunities","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Transl. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41420-024-02223-9","article-title":"Oleanolic acid combined with aspirin plays antitumor roles in colorectal cancer via the Akt\/NF\u03baB\/I\u03baB\u03b1\/COX2 pathway","volume":"10","author":"Zhou","year":"2024","journal-title":"Cell Death Discov."},{"key":"B42","doi-asserted-by":"publisher","first-page":"157030","DOI":"10.1016\/j.phymed.2025.157030","article-title":"Multiple target and regulatory pathways of berberine","volume":"146","author":"Zhou","year":"2025","journal-title":"Phytomedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1930125\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:48:07Z","timestamp":1790660887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1930125\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":42,"alternative-id":["10.3389\/fphar.2026.1930125"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1930125","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1930125"}}